Related Experiment Video
Updated: Aug 23, 2025
10:15
A Preclinical Model to Assess Brain Recovery After Acute Stroke in Rats
Published on: November 6, 2019
8.4K
PHLPP Inhibitor NSC74429 Is Neuroprotective in Rodent Models of Cardiac Arrest and Traumatic Brain Injury
Travis C Jackson1,2, Cameron Dezfulian3,4,5, Vincent A Vagni3,5
1Department of Molecular Pharmacology & Physiology, Morsani College of Medicine, University of South Florida, 12901 Bruce B Downs BLDV, Tampa, FL 33612, USA.
Biomolecules
|October 27, 2022
Summary
Small-molecule inhibitors targeting Pleckstrin homology domain and leucine rich repeat protein phosphatase (PHLPP) show promise for neurological conditions. NSC74429 demonstrated significant neuroprotection in preclinical models of stroke and traumatic brain injury.
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- Pleckstrin homology domain and leucine rich repeat protein phosphatase (PHLPP) knockout models show improved outcomes post-stroke and traumatic brain injury (TBI).
- Small-molecule PHLPP inhibitors offer potential for treating neurological conditions, but data on neuroprotection is limited.
- Existing inhibitors may not be suitable for acute brain injury, necessitating exploration of novel compounds.
Purpose of the Study:
- To evaluate novel PHLPP inhibitors (NSC13378, NSC25247, NSC74429) for neuroprotective potential, focusing on those with favorable central nervous system (CNS) penetration.
- To determine the efficacy of NSC74429 in preclinical models of neuronal injury and acute brain injury.
Main Methods:
- Neuronal cultures were subjected to apoptosis (staurosporine), excitotoxicity (glutamate), and oxidative stress (hydrogen peroxide) to screen PHLPP inhibitors.
- In vivo studies utilized a rat model of asphyxial cardiac arrest and a mouse model of severe TBI.
- NSC74429 was administered via serial dosing over 3 days in animal models.
Main Results:
- NSC74429 exhibited significant neuroprotection in neuronal cultures across multiple insult types at micromolar concentrations.
- Serial dosing of NSC74429 (1 mg/kg) improved hippocampal survival in both rat cardiac arrest and mouse TBI models.
- The compound demonstrated neuroprotective effects against various injury mechanisms.
Conclusions:
- NSC74429 is a promising neuroprotective agent effective across multiple insult mechanisms relevant to acute brain injury.
- Further pharmacokinetic/pharmacodynamic (PK/PD) studies are required to optimize NSC74429 dosing strategies.
- Mechanistic investigations are needed to elucidate the role of PHLPP1/2 inhibition versus off-target effects in NSC74429's neuroprotection.
